The complement system is a fundamental pillar of innate immunity, working in concert with physical barriers (skin and mucous membranes), chemical defenses (gastric acid), and cellular mediators (phagocytes) to maintain biological integrity. Beyond its canonical role in host defense, the complement is a critical regulator of homeostasis. It functions as a potent biochemical bridge, not only augmenting the antimicrobial efficacy of antibodies but also engaging in intricate cross-talk with the coagulation cascade.

Dysregulation or chronic imbalance of the complement system can precipitate sterile thromboinflammation—a pathological state occurring in the absence of active infection. The renal parenchyma is particularly susceptible to complement-mediated damage. This vulnerability manifests in a spectrum of clinical conditions, including immune-mediated glomerulonephritis, thrombotic microangiopathies (TMA), vasculitis, and the progression toward end-stage renal fibrosis.

Complement inhibitors are engineered to terminate aberrant immune responses and mitigate chronic inflammatory damage. The therapeutic strategy is dictated by the hierarchical nature of the complement cascade: generally, upstream inhibition provides more comprehensive anti-inflammatory coverage. However, this potency exists in a state of clinical tension; more profound suppression of the cascade inherently compromises immune surveillance, thereby increasing the patient’s susceptibility to opportunistic secondary infections.

FDA-Approved Complement Inhibitors

Complement inhibitors are now used across multiple medical applications, and their clinical applications continue to expand rapidly.

Table 1. List of FDA approved complement inhibitors, source: https://www.biochempeg.com/article/281.html

Use of PEG in Complement Inhibitors

Polyethylene glycol (PEG) has become a widely adopted modification strategy in the development of complement inhibitors, particularly for improving pharmacokinetics, stability, and overall therapeutic performance.

Several FDA-approved complement therapeutics have incorporated PEG or PEG-like modifications, highlighting its practical value in this field. These include Empaveli, SYFOVRE, Izervay, and Zilbrysq.

Pegcetacoplan: Empaveli® & SYFOVRE®

Pegcetacoplan represents a masterclass in structural engineering. This molecule features a unique dumbbell configuration: two identical 15-amino acid cyclic peptides (derived from Compstatin Cp05) are linked at either end of a 40 kDa linear PEG chain.

This modification extends the half-life from a mere few hours to approximately 8.6 days, enabling a manageable dosing schedule. Moreover, the PEG moiety provides the necessary bulk to reduce renal clearance while enhancing solubility and reducing immunogenicity.

By targeting the C3 master switch, pegcetacoplan controls both intravascular and extravascular hemolysis. This single molecular entity has been successfully bifurcated into two distinct products:

◆ Empaveli (Subcutaneous): The first FDA-approved treatment for C3 Glomerulopathy (C3G) and PNH, offering systemic control.

◆ SYFOVRE (Intravitreal): The first-ever approved therapy for Geographic Atrophy (GA) secondary to AMD, providing localized, precision inhibition within the eye.

Avacincaptad Pegol: Stabilizing the RNA Aptamer (Izervay™)

Approved in 2023, Izervay is a PEGylated RNA aptamer designed to inhibit complement protein C5. Unlike protein-based antibodies, aptamers are susceptible to rapid degradation and renal filtration.

Izervay utilizes an approximately 43 kDa branched PEG molecule covalently bound to the RNA backbone. This branched structure acts as a protective shield, significantly extending the drug's residence time in the vitreous humor and preventing premature systemic absorption, which is critical for treating GA.

Zilucoplan: Precision Linkage (Zilbrysq®)

Zilucoplan, a macrocyclic peptide for generalized Myasthenia Gravis (gMG), demonstrates a more nuanced use of PEG.

Rather than a poly PEG carrier, Zilucoplan incorporates a shorter, monodisperse PEG24 linker that connects a C16 lipid tail to the peptide core. This strategic combination—lipidization paired with a precise PEG linker—facilitates a pharmacokinetic profile optimized for daily self-administered subcutaneous dosing, ensuring steady-state inhibition of the Terminal Complement Complex (TCC).

Enabling Advanced Complement Therapeutics with PEG Solutions

As illustrated by multiple approved therapies, PEGylation has become a critical enabling technology in the design of complement inhibitors. From extending half-life and improving stability to supporting diverse molecular formats such as peptides and RNA aptamers, PEG-based strategies continue to play a central role in optimizing drug performance.

Huateng Pharma is a specialized provider of PEG derivatives, offering a broad portfolio ranging from monodispersed and polydispersed PEGs to multi-arm PEGs and customized PEG linkers. These materials are widely used in advanced drug delivery systems, including complement inhibitors, antibody-drug conjugates (ADCs), and other bioconjugates.

Backed by strong R&D capabilities and scalable manufacturing from milligram to commercial scale, Huateng Pharma supports both early-stage research and later-stage development. With increasing interest in complement-targeted therapies, well-designed PEG materials will continue to be an important foundation for innovation in this field.

References:
[1] Complement inhibition: A whole new world, Nicholas Salupo, Korey Bartolomeo, Elias Bassil, Corey Cavanaugh, Georges Nakhoul, Jonathan Taliercio, Ali Mehdi, Cleveland Clinic Journal of Medicine Apr 2026, 93 (4) 227-236; DOI: 10.3949/ccjm.93a.25076
[2] Watanabe-Kusunoki, K., & Anders, H. (2024). Balancing efficacy and safety of complement inhibitors. Journal of Autoimmunity, 145, 103216. https://doi.org/10.1016/j.jaut.2024.103216 

 
Related Articles:

List of FDA Approved PEGylated Drugs Up to 2026

Monodisperse PEG in Modern Drug Development

What Are PEG Linkers and Their Applications?